Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection
Publication Type:
Journal Article
Source:
Aliment. Pharmacol. Ther, Volume 41, Issue 6, p.544-563 (2015)
Keywords:
administration & dosage,
Adult,
analogs & derivatives,
Antiviral Agents,
Benzimidazoles,
Comparative Study,
complications,
Cost-Benefit Analysis,
Disease,
drug therapy,
Drug Therapy,Combination,
economics,
Fibrosis,
Fluorenes,
genetics,
Genotype,
genotype 1,
HCV,
Health,
Health Care Costs,
Hepacivirus,
hepatitis,
Hepatitis C,
hepatitis C virus,
Hepatitis C,Chronic,
Humans,
Incidence,
Infection,
interferon,
Interferons,
isolation & purification,
Liver,
Liver Cirrhosis,
Liver Diseases,
Male,
Medicine,
methods,
Middle Aged,
Patients,
pegylated,
pegylated interferon,
protease inhibitor,
Quality-Adjusted Life Years,
Research,
Research Support,
Ribavirin,
sofosbuvir,
sustained virologic response,
SVR,
therapeutic use,
therapy,
treatment,
Treatment Outcome,
treatment-naive,
Uridine,
Uridine Monophosphate,
virology
